Skip to main content
Premium Trial:

Request an Annual Quote

Fight the Resistance

Premium

At the University of Michigan Comprehensive Cancer Center, researchers are experimenting with adding an IL-6 inhibitor to Herceptin therapy to prevent HER2-positive breast cancer patients from becoming resistant to the drug, reports Genetic Engineering & Biotechnology News. The Michigan researchers — whose work is published in Molecular Cell — found that breast cancer cells can switch on an IL-6 inflammatory pathway, which then promotes the development of cancer stem cells and leads to tumor growth independent of HER2, GEN says. Blocking the IL-6 pathway inhibits the propagation of these stem cells. In mouse studies, the team found that mice treated with an IL-6 inhibitor remained sensitive to Herceptin.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.